NextStep Robotics

Executive Summary

NextStep Robotics is a Cambridge-based medical device company developing the AMBLE Robotic system, a novel solution for foot drop—a condition where patients cannot lift the front part of their foot during walking. The AMBLE provides graded, variable assistance with each step, aiming to retrain neural pathways and reverse foot drop in patients post-stroke, with multiple sclerosis, or after brain, spinal cord, or traumatic injuries. Founded in 2016, the company is currently in Phase 1 stage, indicating early-stage development, likely focusing on product refinement and initial clinical validation. The system addresses a significant unmet need, as foot drop affects millions globally and current solutions (e.g., ankle-foot orthoses or functional electrical stimulation) have limitations in comfort and efficacy. NextStep Robotics differentiates by offering dynamic, adaptive assistance that promotes neurorehabilitation rather than passive support. With a lean profile and no disclosed funding rounds, NextStep appears to be in the formative stages of commercialization. The company's technology has potential for broad adoption in rehabilitation clinics, especially given the aging population and rising incidence of stroke. Key upcoming catalysts include the completion of a pilot clinical study, submission for FDA 510(k) clearance, or securing a strategic partnership for distribution. However, the early stage and lack of public financial data warrant a moderate conviction score. Success hinges on demonstrating clinical efficacy in a larger trial and navigating regulatory hurdles efficiently.

Upcoming Catalysts (preview)

• Q3 2026Completion of Pilot Clinical Study60% success
• Q1 2027FDA 510(k) Submission50% success
• TBDStrategic Partnership with Rehabilitation Provider40% success